Tagged with Hungary

Hungary Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also at risk.   An Increasing Burden Over 14,000 types of pharmaceuticals are unavailable in Hungarian pharmacies, which is placing an…

Hungary Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase funding and shorten approval times.   According to the Hungarian Association of Innovative Pharma Manufacturers, since 2016 only 48 new…

Hungary Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to increase its standing within the overall Hungarian economy.   Speaking at the inauguration of a new plant for Egis Pharmaceuticals…

Pharma Market Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech Republic is in second place, followed by Romania and Hungary Made with Visme Infographic Maker     The CEE countries that exported…

Clinical Trials Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in the country since 2015 has some stakeholders concerned about the future of Hungary as a regional clinical trials hub.   …

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Hungary One of the most salient challenges crippling Hungary’s effort to move the health agenda forward is the mass exodus of healthcare practitioners—placing significant pressures on an already overwhelmed system. “If we take the case of pathology as a small specialty among other important specialties in Hungary, we are only 250…

Hungary Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through mandatory tax contributions from employers and employees. “From a drug reimbursement point of view, we have one of the most complex and comprehensive regulatory frameworks in Europe, which aims to cover all medical and medicinal needs…

Hungary Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence and support of Italy-based Kedrion Biopharma has the company been able to transform into the powerhouse that is today.  …

Hungary While pharmaceutical products and healthcare financing dominate the majority of discussions surrounding the improvement of health outcomes, health literacy still remains a core issue that, if left unaddressed, may vary well hinder Hungary’s ability to push its health agenda forward and create a more sustainable system moving forward.   According…

Health This chart shows the varying levels of health literacy in Europe. Health literacy is a serious issue in Hungary where 19% of the population have ‘inadequate’ knowledge and 33% are rated as ‘problematic.’ Click here to read more articles and interviews from Hungary

Hungary Hungary’s medicinal biotech companies are clustered in the country’s four major university towns: Budapest, Debrecen, Szeged and Pécs, with the majority basing themselves in the capital, Budapest. Click here to read more articles and interviews from Hungary